gms | German Medical Science

The global antimalarial pipeline has been strengthened in recent years with the delivery of new artemisinin combination therapies, promising new clinical candidates and early stage discovery projects. This talk will focus on the challenges that remain and the strategy adopted by Medicines for Malaria Venture (MMV) in targeting eradication. MMV’s focus has shifted from the treatment of blood stage malaria infections and now also includes relapse prevention, blocking of transmission and the protection of vulnerable populations in areas with little or no transmission.

New target product profiles and target candidate profiles defining the specific characteristics of individual molecules for asexual blood stage cures, transmission blocking, vivax and chemoprotection will be described.

Finally strategies will be presented how obtain earlier information and confirmation on antimalarial activity in humans.